Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE Rejects Roche’s Avastin In Advanced Ovarian Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

The U.K.'s health care cost regulator says it wouldn't recommend Roche's Avastin as a first-line treatment for advanced ovarian cancer along with standard chemotherapy, on grounds it doesn’t offer value for money.

You may also be interested in...



NICE Rejects Avastin For Ovarian Cancer On Cost, Okays Lucentis

NICE has knocked back Avastin for ovarian cancer due to high cost, but Roche may have a plausible market strategy in place for the drug in the UK.

NICE Rejects Roche’s Avastin For Ovarian Cancer Due To Excessive Cost

Roche’s extremely high price for Avastin results in yet another knock-back by Britain’s NICE, this time for advanced ovarian cancer.

NICE Turns Down Avastin For Yet Another Indication In Draft Guidance

The U.K.’s NICE issues draft guidance recommending against use of Avastin for first recurrence of platinum-sensitive advanced ovarian cancer, citing evidence and cost-effectiveness issues.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1131980

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel